These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 18056045)

  • 1. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.
    Russell RG; Xia Z; Dunford JE; Oppermann U; Kwaasi A; Hulley PA; Kavanagh KL; Triffitt JT; Lundy MW; Phipps RJ; Barnett BL; Coxon FP; Rogers MJ; Watts NB; Ebetino FH
    Ann N Y Acad Sci; 2007 Nov; 1117():209-57. PubMed ID: 18056045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates: the first 40 years.
    Russell RG
    Bone; 2011 Jul; 49(1):2-19. PubMed ID: 21555003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between the chemistry and biological activity of the bisphosphonates.
    Ebetino FH; Hogan AM; Sun S; Tsoumpra MK; Duan X; Triffitt JT; Kwaasi AA; Dunford JE; Barnett BL; Oppermann U; Lundy MW; Boyde A; Kashemirov BA; McKenna CE; Russell RG
    Bone; 2011 Jul; 49(1):20-33. PubMed ID: 21497677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates: mode of action and pharmacology.
    Russell RG
    Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates: from bench to bedside.
    Russell RG
    Ann N Y Acad Sci; 2006 Apr; 1068():367-401. PubMed ID: 16831938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA; Rodan GA
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.
    Russell RG; Watts NB; Ebetino FH; Rogers MJ
    Osteoporos Int; 2008 Jun; 19(6):733-59. PubMed ID: 18214569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiology of the aging bone and mechanisms of action of bisphosphonates.
    Dominguez LJ; Di Bella G; Belvedere M; Barbagallo M
    Biogerontology; 2011 Oct; 12(5):397-408. PubMed ID: 21695491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates: preclinical review.
    Green JR
    Oncologist; 2004; 9 Suppl 4():3-13. PubMed ID: 15459425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates: The role of chemistry in understanding their biological actions and structure-activity relationships, and new directions for their therapeutic use.
    Ebetino FH; Sun S; Cherian P; Roshandel S; Neighbors JD; Hu E; Dunford JE; Sedghizadeh PP; McKenna CE; Srinivasan V; Boeckman RK; Russell RGG
    Bone; 2022 Mar; 156():116289. PubMed ID: 34896359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
    Stresing V; Fournier PG; Bellahcène A; Benzaïd I; Mönkkönen H; Colombel M; Ebetino FH; Castronovo V; Clézardin P
    Bone; 2011 Feb; 48(2):259-66. PubMed ID: 20920623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite.
    Nancollas GH; Tang R; Phipps RJ; Henneman Z; Gulde S; Wu W; Mangood A; Russell RG; Ebetino FH
    Bone; 2006 May; 38(5):617-27. PubMed ID: 16046206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bisphosphonates: from the laboratory to the clinic and back again.
    Russell RG; Rogers MJ
    Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonates, specific inhibitors of osteoclast function and a class of drugs for osteoporosis therapy.
    Li B; Ling Chau JF; Wang X; Leong WF
    J Cell Biochem; 2011 May; 112(5):1229-42. PubMed ID: 21465521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bisphosphonates: the molecular targets and mechanisms of action].
    Wada S; Kamiya S; Ono K
    Clin Calcium; 2005 May; 15(5):819-24. PubMed ID: 15876745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy.
    Leu CT; Luegmayr E; Freedman LP; Rodan GA; Reszka AA
    Bone; 2006 May; 38(5):628-36. PubMed ID: 16185944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298.
    Coxon FP; Helfrich MH; Van't Hof R; Sebti S; Ralston SH; Hamilton A; Rogers MJ
    J Bone Miner Res; 2000 Aug; 15(8):1467-76. PubMed ID: 10934645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of action of bisphosphonates: current status.
    Roelofs AJ; Thompson K; Gordon S; Rogers MJ
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effects of bisphosphonates.
    Green JR
    Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.